← Companies
OMEROS CORP
Data as of Oct 9, 2026
OMER
CIK 1285819Reported federal lobbying
$1.1M
27 filings · latest Jul 21, 2026
Federal contracts since 2024
$0
2 awards · latest Aug 28, 2026
Lobbying
$1,105,000 in reported federal lobbying spend across 27 quarterly filings, most recently Jul 21, 2026. Amounts are the sums companies and their registrants report on Lobbying Disclosure Act filings; a filing that covers several issues counts its full amount under each.
Spend by issue
- Medical/Disease Research/Clinical Labs$230K4 filings
- Medicare/Medicaid +1$190K7 filings
- Medicare/Medicaid$180K4 filings
- Health Issues$140K3 filings
- Medical/Disease Research/Clinical Labs +1$125K2 filings
- Health Issues +1$80K1 filing
Latest filings, Jan 2026 onward
| Filed | Registrant and subject | Amount |
|---|---|---|
| Jul 21, 2026 | THE PETRIZZO GROUP, INC. for OMEROS CORPORATION Health Issues · Medical/Disease Research/Clinical Labs Issues involving the rare pediatric disease priority review voucher.
Issues involving the rare pediatric disease priority review voucher. | $0 |
| Jul 15, 2026 | THE NICKLES GROUP, LLC for OMEROS CORPORATION Medicare/Medicaid · Health Issues Monitored separate payment policy for nonopioid alternatives. Monitored issues involving rare disease therapies.
Monitored issues related to rare pediatric disease and Priority Review Vouchers (PRVs). | $0 |
| Apr 19, 2026 | AQUIA GROUP, LLC for OMEROS CORPORATION Unspecified | $0 |
| Apr 8, 2026 | THE NICKLES GROUP, LLC for OMEROS CORPORATION Medicare/Medicaid · Health Issues Monitored separate payment policy for nonopioid alternatives. Monitored issues involving rare disease therapies.
Monitored issues related to rare pediatric disease and Priority Review Vouchers (PRVs). | $0 |
| Jan 20, 2026 | AQUIA GROUP, LLC for OMEROS CORPORATION Medical/Disease Research/Clinical Labs Issues related to rare pediatric disease | $90,000 |
| Jan 15, 2026 | THE NICKLES GROUP, LLC for OMEROS CORPORATION Medicare/Medicaid · Health Issues Monitored separate payment policy for nonopioid alternatives. Monitored issues involving rare disease therapies.
Monitored issues related to rare pediatric disease and Priority Review Vouchers (PRVs). | $0 |